Compare Cardinal Health Inc (CAH) vs The Coca-Cola Co K (KO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cardinal Health Inc vs The Coca-Cola Co K — how do they compare? Cardinal Health Inc trades at $228.91 (market cap $53.89B), while The Coca-Cola Co K trades at $82.75 (market cap $357.45B). The key difference: The Coca-Cola Co K is far larger — about 6.6× Cardinal Health Inc's market cap, and The Coca-Cola Co K pays the higher dividend (2.55%). Which is the better fit depends on your goals.
| CAH | KO | |
|---|---|---|
Market Cap | $53.89B | $357.45B |
Sector | Health | Consumer Staples |
52-Week High | $239.71 | $84.25 |
52-Week Low | $146.04 | $65.67 |
Enterprise Value | $58.87B | $387.52B |
Dividend Yield | 0.89% | 2.55% |
Volume | — | 14,630,257 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cardinal Health (CAH) trades at $233.66, down 0.91% in the last session, with a bullish technical signal from moving averages and strong analyst support. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $3.17 surpassing expectations. Revenue reached $222.58 billion in 2025, though net margins remain thin at 0.62%. Recent news highlights growth potential in medical supplies, with earnings results for fiscal 2026 due August 11.
The outlook for CAH is positive, driven by earnings momentum and sector tailwinds, but risks include high leverage with debt-to-asset ratio at 16.09% and competitive pressures. Analyst consensus is bullish with a $248 price target, suggesting 6% upside. Investors should weigh solid operational cash flow against negative shareholder equity and investing outflows.
Coca-Cola (KO) trades at $83.25, down 1.19% on the day, with a bullish technical outlook supported by moving averages and strong institutional buying activity. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $0.86 exceeding expectations. Fundamentals show solid profitability with a 27.8% net income margin and 45.8% ROE, while valuation ratios like P/E of 26.13 reflect premium pricing. Recent news highlights steady demand trends and dividend reliability, with the stock offering a 2.5% yield.
The outlook for KO remains positive given consistent earnings outperformance, analyst consensus buy rating (60% buy), and a $89.75 price target implying 7.8% upside. Key risks include regional demand volatility in Asia and high debt levels, but the company's strong brand and cash flow support dividend sustainability. Investors may find value in its defensive qualities and growth potential from global events like the FIFA World Cup 2026 sponsorship.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cardinal Health Inc
Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
Read more on CAH →About The Coca-Cola Co K
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →
